<DOC>
	<DOC>NCT01138969</DOC>
	<brief_summary>Proton Pump Inhibitors (PPI) can prevent the recurrence of peptic ulcer in clopidogrel users.</brief_summary>
	<brief_title>Efficacy of Proton Pump Inhibitor in Prevention of Clopidogrel-related Peptic Ulcer</brief_title>
	<detailed_description>The aim of the prospective, randomized study is to investigate the efficacy of PPI in prevention of ulcer recurrence for clopidogrel users. We plan to enroll 300 clopidogrel users without baseline gastroduodenal ulcer at initial endoscopy. The patients will be randomly assigned to receive either (1) esomeprazole (20 mg qd) plus clopidogrel or (2) clopidogrel treatment alone for 6 months. The ulcer recurrence rate between the treatment groups will be compared.</detailed_description>
	<mesh_term>Ulcer</mesh_term>
	<mesh_term>Peptic Ulcer</mesh_term>
	<mesh_term>Clopidogrel</mesh_term>
	<mesh_term>Ticlopidine</mesh_term>
	<mesh_term>Esomeprazole</mesh_term>
	<mesh_term>Proton Pump Inhibitors</mesh_term>
	<criteria>We plan to enroll 300 clopidogrel users without baseline gastroduodenal ulcer at initial endoscopy. The patients will be randomly assigned to receive either (1) esomeprazole (20 mg qd) plus clopidogrel or (2) clopidogrel treatment alone for 6 months. 1.serious disease 2.refuse informed consent</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2015</verification_date>
	<keyword>proton pump inhibitor</keyword>
	<keyword>peptic ulcer</keyword>
	<keyword>clopidogrel</keyword>
	<keyword>prevention</keyword>
</DOC>